Navigation Links
FDA: Tortoise, hare, or something else?

Editor's note: This is part I of a two-part column on the Food and Drug Administration approval process.

Last year, this column highlighted the debate around drug and device safety. At that time, I expected that the controversy would continue to grow.

Ind......

Full article >>> 6 congressional hearing, Waxman stated, The FDA never required the manufacturer to [conduct] a thorough post-market study of Avandia's heart risks, noting that the FDA requires such safety studies after drugs are approved.

Safety takes a back seat

As pointed out in previous columns, safety has always been a concern ever since Hippocrates laid out the dictum of First, Do N......

Full article >>> ewise, in using drugs or devices for preventive purposes, safety becomes that much more important. It's hard to justify a safety risk in the context of a condition with no symptoms.

As the Avandia story reached the front pages, a number of related side stories also appeared. One recent report ......

Full article >>> standard for drug approval is demonstrated efficacy - namely that the drug works. Safety also is a part of the process and ordinarily there are fairly extensive preclinical and animal studies designed to ferret out unsafe drugs. Most of these studies are fairly routine safety tests that simply set the backdrop to the real clinical trials that are of large enough size, or are of clever enough desig......

Full article >>>
Ogan Gurel: Abbott vs. Thailand has implications for innovation and access

Ogan Gurel: Personalized medicine and technology convergence

Of private equity, research, and drug development

<......

Full article >>>
'"/>

Source:wistechnology.com By Dr. Ogan Gurel 06/20/07


Related biology technology :

1. This FlashMob is something super
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):